drugset / Trial / NCT00970281

A Study of Olanzapine in Patients With Schizophrenia

NCT00970281

Phase 3 Completed 91 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than intramuscular placebo by comparing changes from baseline to 2 hours after the first IM injection of agitation.

Timeline

Start
2009-09
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 10 mg Intramuscular

Indications